Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

The review aims to consolidate research findings on the molecular mechanisms and
virulence and pathogenicity characteristics of coronavirus disease (COVID-19) causative …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …

Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The
active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …

The outbreak of a novel coronavirus associated with acute respiratory disease, called
COVID‐19, marked the introduction of the third spillover of an animal coronavirus (CoV) to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread in
humans in almost every country, causing the disease COVID-19. Since the start of the …

SARS-CoV-2 virus, the causative agent of COVID-19 pandemic, has a genomic organization
consisting of 16 nonstructural proteins (nsps), 4 structural proteins, and 9 accessory …

Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly
developed to help restore the massive health and economic disruption caused by the …